close
References
  1. Kahn TS. Off spells and dyskinesias: pharmacologic management of motor complications. Cleve Clin J Med. 2012;79(Suppl 2):S8-13.
  2. Espay AJ. Management of motor complications in Parkinson disease: current and emerging therapies. Neurol Clin. 2010;28:913-925.
  3. Ensam prescribing information. Revised February 2008. Briston-Myers Squibb. Princeton, New Jersey. 2008.
  4. Okun MS. Deep brain stimulation for Parkinson’s disease. N Engl J Med. 2012;367:1529-1538.
  5. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease. Arch Neurol. 2011;68:165-171.
  6. Thevathasan W, Coyne TJ, Hyam JA, et al. Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. Neurosurgery. 2011;69:1248-1253.
  7. Anderson KE. Dementia in Parkinson's disease. Curr Treat Options Neurol. 2004;6:201-207.
  8. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70:1017-1022.
  9. Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol. 2009;10:9:23.
  10. Anderson KE. Behavioral disturbances in Parkinson's disease. Dialogues Clin Neurosci. 2004;6:323-332.
  11. Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf. 2010;9:167-176.
  12. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504.
  13. Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84:14-17.
  14. Lyons KE, Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. Am J Manag Care. 2011;17(Suppl 12):S308-S314.
  15. Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25:2493-2500.
  16. Cheng EM, Tonn S, Swain-Eng R, et al. Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology. 2010;75:2021-2027.
  17. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.
  18. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316.
  19. Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression. An update of the 2007 Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality; 2011.
  20. Trotti LM. REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging. 2010;27:457-470.
  21. Rosenberg R, Bogan R. Armodafinil in the treatment of excessive sleepiness. Nat Sci Sleep. 2010;2:95-105.
  22. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson's disease. Neurology. 2004;62:177-180.
  23. Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Movement Disorders. 2008;23:1361-1369.